Pelthos Therapeutics Inc.
New York Stock Exchange ArcaCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Scott Plesha
- Full Time Employees
- 92
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703 Durham NC United States of America 27703
- IPO Date
- Feb 16, 2024
- CIK
- 0001919246
- Website
- pelthos.com
- Similar Companies
- Business
- Pelthos Therapeutics Inc. (NYSE American: PTHS) is a clinical-stage biopharmaceutical company that develops and commercializes innovative, non-opioid therapeutic products, primarily utilizing its proprietary nitric oxide-based NITRICIL technology platform, to address unmet needs in dermatology and pain management; its lead product ZELSUVMI (berdazimer topical gel, 10.3%) treats molluscum contagiosum in adults and pediatric patients aged one year and older as the first FDA-approved at-home prescription therapy, while recently acquired XEPI (ozenoxacin cream, 1%) targets impetigo caused by Staphylococcus aureus or Streptococcus pyogenes in patients two months and older, with additional pipeline candidates leveraging NITRICIL for other dermatological conditions. Founded in 2002 and headquartered at 4020 Stirrup Creek Drive, Suite 110, Durham, North Carolina, the company operates principally in the United States, focusing on pediatric and adult dermatology markets through commercial infrastructure supporting at-home treatments. In July 2025, Pelthos completed a merger with Channel Therapeutics (formerly Channel Therapeutics Corporation, renamed Pelthos Therapeutics Inc. in the same month), raised $50.1 million in equity financing including from Ligand Pharmaceuticals, and launched ZELSUVMI commercially; subsequent developments include an $18 million convertible notes financing in November 2025 to fund the $4.2 million acquisition of XEPI rights from Biofrontera and Ferrer, plus a December 2025 pharmacy benefit manager agreement via a group purchasing organization adding ZELSUVMI to formularies covering over 20 million lives effective December 1.
Company News
Pelthos Therapeutics Q2 Earnings Call Highlights
Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Pelthos Therapeutics Q1 Earnings Call Highlights
Pelthos Therapeutics Inc. (PTHS) Q1 2026 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Reports Q1 Loss, Beats Revenue Estimates
Pelthos Therapeutics Announces First Quarter 2026 Financial Results
Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026
Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Richard Malamut Sells 590 Shares of Stock
Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Peter Greenleaf Sells 797 Shares
Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Ezra Friedberg Sells 558 Shares
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
Pelthos Therapeutics Q4 Earnings Call Highlights
Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript
Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates